Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Solid tumors require blood vessels for growth, and many new cancer therapies are directed against the tumor vasculature. The widely held view is that these antiangiogenic therapies should destroy the tumor vasculature, thereby depriving the tumor of oxygen and nutrients. Here, I review emerging evidence supporting an alternative hypothesis—that certain antiangiogenic agents can also transiently “normalize” the abnormal structure and function of tumor vasculature to make it more efficient for oxygen and drug delivery. Drugs that induce vascular normalization can alleviate hypoxia and increase the efficacy of conventional therapies if both are carefully scheduled. A better understanding of the molecular and cellular underpinnings of vascular normalization may ultimately lead to more effective therapies not only for cancer but also for diseases with abnormal vasculature, as well as regenerative medicine, in which the goal is to create and maintain a functionally normal vasculature.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, the aberrant vasculature also restricts the access of recruited immune cells and anticancer therapeutics to tumors, resulting in reduced outcomes of cancer treatments.[ 18 ]”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [18]
In the citing paper
“Recently, research groups such as Jain, et al., have used the combination therapy of angiogenesis inhibitors along with chemotherapy [24], where the angiogenesis modulators are used to normalize the vasculature and improve the EPR effect–mediated drug delivery and efficacy of the cancer treatment.”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [24]
In the citing paper
“Because the tumor vasculature is immature (12) and lacks myogenic and autonomic regulation (5)”
In the citing paper
“Conversely, increased glycolytic rate and low perfusion/oxygenation contribute to intratumoral hypoxia and acidosis, which is alleviated with enhanced perfusion (12).”
In the citing paper
“A rationale for combining anti-VEGF therapy with chemotherapy is that anti-VEGF therapy caused tumor vasculature to normalize resulting in increased drug delivery to tumors [123].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [123]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Self-citationAngiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Molecular regulation of vessel maturation
Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,529
Self-citation
Research works printed but not linked: 12
- D. J. Hicklin L. M. Ellis J. Clin. Oncol. in press.
- J. Ma et al., Cancer Res.61, 5491 (2001).
- R. K. Jain, in Clinical Oncology, M. Abeloff et al., Eds. (Elsevier, New York, ed. 3, 2004), pp. 153–172.
- R. K. Jain, Clin. Cancer Res.5, 1605 (1999).
- C. G. Lee et al., Cancer Res.60, 5565 (2000).
- A. Kadambi et al., Cancer Res.61, 2404 (2001).
- M. Relf et al., Cancer Res.57, 963 (1997).
- Y. Izumi, L. Xu, E. di Tomaso, D. Fukumura, R. K. Jain, Nature416, 279 (2002).
- P. Perrotte et al., Clin. Cancer Res.5, 257 (1999).
- P. M. Gullino, in Biomedical Thermology, M. Gautherie, E. Albert, Eds. (A. R. Liss, New York, 1982), pp. 1–20.
- L. Flintoft, Nature Rev. Cancer4, 754 (2004).
- G. Griffon-Etienne, Y. Boucher, C. Brekken, H. D. Suit, R. K. Jain, Cancer Res.59, 3776 (1999).
Cited by
Items 401–500 of 1,035
Datta, M., Via, L. E., Kamoun, W. S., Liu, C., Chen, W., Seano, G., Weiner, D. M., Schimel, D., England, K., Martin, J. D., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424563112 · Cited by 207
“In this study we show, for the first time to our knowledge, in a rabbit model of TB that treatment with bevacizumab normalizes granuloma vasculature, reduces hypoxia, and enhances small molecule delivery during a “window of normalization,” a transient effect observed in tumors (15, 20).”
BackgroundSelf-citationTipping the Balance: Robustness of Tip Cell Selection, Migration and Fusion in Angiogenesis
Bentley, K., Mariggi, G., Gerhardt, H., & Bates, P. A. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000549 · Cited by 204
“Normalisation also improves drug delivery by creating better supply lines to the tumour cells [6].”
BackgroundTugues, S., Koch, S., Gualandi, L., Li, X., & Claesson-Welsh, L. (2011) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.04.004 · Cited by 205
Recent Advances in Nanostrategies Capable of Overcoming Biological Barriers for Tumor Management
Huo, D., Jiang, X., & Hu, Y. (2020) · Advanced Materials · doi:10.1002/adma.201904337 · Cited by 205
Chelvanambi, M., Fecek, R. J., Taylor, J. L., & Storkus, W. J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001906 · Cited by 201
“To distinguish how therapy impacted the day 18 TIL repertoire, we performed TCRseq analyzes of the TCR β -CDR3 repertoires of TILs and animal-matched splenocytes isolated from STING agonist-treated versus control-treated tumor-bearing mice.”
BackgroundMethodCrane, C. H., Ellis, L. M., Abbruzzese, J. L., Amos, C., Xiong, H. Q., Ho, L., Evans, D. B., Tamm, E. P., Ng, C., Pisters, P. W. T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6780 · Cited by 206
Manning, E. A., Ullman, J. G. M., Leatherman, J. M., Asquith, J. M., Hansen, T. R., Armstrong, T. D., Hicklin, D. J., Jaffee, E. M., & Emens, L. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0374 · Cited by 205
Ferrara, N. (2010) · Nature Medicine · doi:10.1038/nm1010-1107 · Cited by 203
Tumor cell cycle arrest induced by shear stress: Roles of integrins and Smad
Chang, S.-F., Chang, C. A., Lee, D.-Y., Lee, P.-L., Yeh, Y.-M., Yeh, C.-R., Cheng, C.-K., Chien, S., & Chiu, J.-J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712353105 · Cited by 201
“Normalization of tumor vasculature has emerged as an important concept in antiangiogenic therapy, and this may alter interstitial f low environment and enhance drug delivery (3, 19).”
BackgroundKienast, Y., Klein, C., Scheuer, W., Raemsch, R., Lorenzon, E., Bernicke, D., Herting, F., Yu, S., The, H. H., Martarello, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0081 · Cited by 201
Nanotechnology platforms and physiological challenges for cancer therapeutics
Kim, K. Y. (2007) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2006.12.002 · Cited by 201
“[33] Jain RK.”
BackgroundMulticellular Vascularized Engineered Tissues through User‐Programmable Biomaterial Photodegradation
Arakawa, C. K., Badeau, B. A., Zheng, Y., & DeForest, C. A. (2017) · Advanced Materials · doi:10.1002/adma.201703156 · Cited by 200
Tumor vessel normalization after aerobic exercise enhances chemotherapeutic efficacy
Schadler, K. L., Thomas, N. J., Galie, P. A., Bhang, D. H., Roby, K. C., Addai, P., Till, J. E., Sturgeon, K., Zaslavsky, A., Chen, C. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11748 · Cited by 199
“Tumor vascular normalization includes a decrease in non-functional sprouts, an increase in hierarchical vasculature with reduced leakiness, and no change in microvessel density, resulting in increased blood delivery [2].”
BackgroundResistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies
Bottsford-Miller, J. N., Coleman, R. L., & Sood, A. K. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.9242 · Cited by 199
“Under hypoxic conditions resulting from anti-VEGF treatment, a compensatory release of proangiogenic cytokines generates vessels characterized by irregular borders, hypermobile cells, loosely attached layers, and denuded areas.(34,57) In PHD-2 heterozygous mice, endothelial cells upregulate VEGFR-1 and VE-cadherin to…”
BackgroundInfluentialThe Billion Cell Construct: Will Three-Dimensional Printing Get Us There?
Miller, J. S. (2014) · PLoS Biology · doi:10.1371/journal.pbio.1001882 · Cited by 199
Al-Abd, A. M., Alamoudi, A. J., Abdel-Naim, A. B., Neamatallah, T. A., & Ashour, O. M. (2017) · Journal of Advanced Research · doi:10.1016/j.jare.2017.06.006 · Cited by 198
“Vascular normalization is accompanied by improved intratumoral perfusion characteristics and better delivery of nutrients, oxygen and chemotherapeutic agents themselves to deeper micro-regions of solid tumors [159].”
BackgroundThe Tumor Vascular Endothelium as Decision Maker in Cancer Therapy
Klein, D. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00367 · Cited by 196
“Further on, the structural abnormalities like poorly interconnected endothelial cells, no regular associated mural cells, and abundance of vesiculo-vacuolar organelles contribute to the leaky, hyper-permeable phenotype, finally causing extravasation of intravascular fluids and plasma proteins (37, 38).”
BackgroundPotentialities of selenium nanoparticles in biomedical science
Nayak, V., Singh, K. R., Singh, A. K., & Singh, R. P. (2021) · New Journal of Chemistry · doi:10.1039/d0nj05884j · Cited by 195
Santos, A. A., Lopes, C. C., Ribeiro, J. R., Martins, L. R., Santos, J. C., Amorim, I. F., Gärtner, F., & Matos, A. J. (2013) · BMC Veterinary Research · doi:10.1186/1746-6148-9-1 · Cited by 195
“Furthermore, it has been suggested that VEGF could be an early carcinogenic factor that declines with malignant progression [31], a hypothesis that may justify our results.”
ResultAngiogenic factors as potential drug target: Efficacy and limitations of anti-angiogenic therapy
Gacche, R. N., & Meshram, R. J. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.05.002 · Cited by 193
“improved efficacy of combination therapy with anti-angiogenic drugs [150].”
BackgroundHendry, S. A., Farnsworth, R. H., Solomon, B., Achen, M. G., Stacker, S. A., & Fox, S. B. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00621 · Cited by 188
“Newly formed blood vessels within tumors, however, are structurally and functionally abnormal, lacking the specialized organization of normal tissue vasculature (147).”
BackgroundLipid nanoparticle delivery systems for siRNA-based therapeutics
Wan, C., Allen, T. M., & Cullis, P. R. (2014) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0161-z · Cited by 193
“blood vessels that feed the tumor cells [102, 103].”
BackgroundImmunomodulatory Activity of VEGF in Cancer
(2017) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2016.09.007 · Cited by 194
Farnsworth, R. H., Lackmann, M., Achen, M. G., & Stacker, S. A. (2014) · Oncogene · doi:10.1038/onc.2013.304 · Cited by 193
Targeting brain metastases in ALK-rearranged non-small-cell lung cancer
Zhang, I., Zaorsky, N. G., Palmer, J. D., Mehra, R., & Lu, B. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00013-3 · Cited by 193
Tumor angiogenesis revisited: Regulators and clinical implications
Ronca, R., Benkheil, M., Mitola, S., Struyf, S., & Liekens, S. (2017) · Medicinal Research Reviews · doi:10.1002/med.21452 · Cited by 193
Panagi, M., Voutouri, C., Mpekris, F., Papageorgis, P., Martin, M. R., Martin, J. D., Demetriou, P., Pierides, C., Polydorou, C., Stylianou, A., et al. (2020) · Theranostics · doi:10.7150/thno.36936 · Cited by 191
“Vascular normalization is based on the judicious use of anti-angiogenic agents to target vessel permeability [6, 19], while normalization of the tumor interstitial space is based on the use of drugs exerting anti-fibrotic properties that normalize the tumor extracellular matrix in order to alleviate forces and”
BackgroundA comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
Riccardi, F., Dal Bo, M., Macor, P., & Toffoli, G. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1274088 · Cited by 188
“…may extend the ef fi cacy of treatment to antigen-negative cells found in the tumor niche, to cells that form the core of the tumor mass being less accessible to the ADC (Jain, 2005; Mahadevan and Von Hoff, 2007; Xiao and Yu, 2021), and to cells that have low/heterogeneous expression of the antigen.”
BackgroundTargeting the tumour vasculature: from vessel destruction to promotion
Guelfi, S., Hodivala-Dilke, K., & Bergers, G. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00736-0 · Cited by 183
“Vascular normalization has been proposed 182 as a process whereby initial effects of anti-angiogenic therapy cause temporary pruning, fortification and decompression of tumour blood vessels 183,184 and provide a transient therapeutic window for improving the efficacy of radiation and cytotoxic…”
PET Monitoring of Therapy Response in Head and Neck Squamous Cell Carcinoma
Schöder, H., Fury, M., Lee, N., & Kraus, D. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057208 · Cited by 192
“Ultimately, these properties limit the build-up of sufficient drug concentrations within the tumor (24) and promote the development of hypoxic tumor subregions.”
BackgroundStructural Adaptation and Heterogeneity of Normal and Tumor Microvascular Networks
Pries, A. R., Cornelissen, A. J. M., Sloot, A. A., Hinkeldey, M., Dreher, M. R., Höpfner, M., Dewhirst, M. W., & Secomb, T. W. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000394 · Cited by 192
“Delivery of cytotoxic agents via the blood circulation is impaired due to the heterogeneous blood flow distribution [2,7].”
BackgroundNumerical Modeling of Fluid Flow in Solid Tumors
Soltani, M., & Chen, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020344 · Cited by 190
“Cancer is the second leading cause of death, causing one of every four deaths in North America [1].”
BackgroundThe hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis
You, W.-K., & McDonald, D. M. (2008) · BMB Reports · doi:10.5483/bmbrep.2008.41.12.833 · Cited by 190
Tumor Abnormality-Oriented Nanomedicine Design
Zhou, Q., Xiang, J., Qiu, N., Wang, Y., Piao, Y., Shao, S., Tang, J., Zhou, Z., & Shen, Y. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00062 · Cited by 188
Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines
Durymanov, M. O., Rosenkranz, A. A., & Sobolev, A. S. (2015) · Theranostics · doi:10.7150/thno.11742 · Cited by 189
Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications
Fan, X., Rai, A., Kambham, N., Sung, J. F., Singh, N., Petitt, M., Dhal, S., Agrawal, R., Sutton, R. E., Druzin, M. L., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci76864 · Cited by 189
“Although sFLT1 is an endogenous antagonist of both VEGF and placental growth factor (PLGF) (3), the maternal symptoms of preeclampsia most likely result from interference with VEGF signaling in the mother (2, 9, 10).”
Extravasation of polymeric nanomedicines across tumor vasculature
Danquah, M. K., Zhang, X. A., & Mahato, R. I. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.11.005 · Cited by 188
Kim, S., Loevner, L. A., Quon, H., Kilger, A., Sherman, E., Weinstein, G., Chalian, A., & Poptani, H. (2010) · American Journal of Neuroradiology · doi:10.3174/ajnr.a1817 · Cited by 190
“However, delivery of the drug and oxygen is often impeded by abnormal blood vessels and the presence of tumor cells farther away from functional vasculature.(1) It has been demonstrated that the rapid onset or reversal of tumor vascular normalization during antiangiogenic therapy can be detected by MR imaging techniqu…”
BackgroundConcerns about anti-angiogenic treatment in patients with glioblastoma multiforme
Verhoeff, J. J., van Tellingen, O., Claes, A., Stalpers, L. J., van Linde, M. E., Richel, D. J., Leenders, W. P., & van Furth, W. R. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-444 · Cited by 189
“Vessel normalisation is believed to explain the synergy between bevacizumab and chemotherapy in advanced colorectal cancer patients [9,57].”
BackgroundCancer chemotherapy resistance: Mechanisms and recent breakthrough in targeted drug delivery
Davodabadi, F., Sajjadi, S. F., Sarhadi, M., Mirghasemi, S., Nadali Hezaveh, M., Khosravi, S., Kamali Andani, M., Cordani, M., Basiri, M., & Ghavami, S. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176013 · Cited by 184
VEGF inhibition: insights from preclinical and clinical studies
Crawford, Y., & Ferrara, N. (2009) · Cell and Tissue Research · doi:10.1007/s00441-008-0675-8 · Cited by 188
“Increased oxygenation would enhance the efficacy of radiation therapy (Jain 2005).”
BackgroundA microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis
Vecchione, A., Belletti, B., Lovat, F., Volinia, S., Chiappetta, G., Giglio, S., Sonego, M., Cirombella, R., Onesti, E. C., Pellegrini, P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305472110 · Cited by 188
“The concomitant modulation of the VEGFB and VEGFR2 leads to a normalization of the tumor microenvironment through the control of new vessel formation and maturation, thus improving cancer treatment (21, 22).”
BackgroundInterfering with Tumor Hypoxia for Radiotherapy Optimization
Telarovic, I., Wenger, R. H., & Pruschy, M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02000-x · Cited by 185
Choi, Y., & Jung, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01114-w · Cited by 188
Kashiwagi, S., Izumi, Y., Gohongi, T., Demou, Z. N., Xu, L., Huang, P. L., Buerk, D. G., Munn, L. L., Jain, R. K., & Fukumura, D. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24015 · Cited by 188
Self-citationIntratumoral Drug Delivery with Nanoparticulate Carriers
Holback, H., & Yeo, Y. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0360-y · Cited by 187
“therapy, thereby facilitating oxygen and drug delivery (134).”
BackgroundMaione, F., Capano, S., Regano, D., Zentilin, L., Giacca, M., Casanovas, O., Bussolino, F., Serini, G., & Giraudo, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58976 · Cited by 187
“It is well documented that, as a result of architectural and biological abnormalities such as tortuosity, leakiness, and lack of pericytes, tumor blood vessels are structurally and functionally aberrant (5), causing cancer tissue hypoxia (6).”
InfluentialGoede, V, Coutelle, O., Neuneier, J., Reinacher-Schick, A., Schnell, R., Koslowsky, T. C., Weihrauch, M. R., Cremer, B., Kashkar, H., Odenthal, M., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605925 · Cited by 186
“Such stromal alterations are part of the vascular ‘normalisation’ process induced by bevacizumab and contribute to more efficient delivery of chemotherapeutic agents (Jain, 2005; Jain et al, 2006).”
BackgroundGomes-Santos, I. L., Amoozgar, Z., Kumar, A. S., Ho, W. W., Roh, K., Talele, N. P., Curtis, H., Kawaguchi, K., Jain, R. K., & Fukumura, D. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0499 · Cited by 181
“Conversely, increased glycolytic rate and low perfusion/oxygenation contribute to intratumoral hypoxia and acidosis, which is alleviated with enhanced perfusion (12).”
BackgroundSelf-citationThe challenge of targeting metastasis
Fidler, I. J., & Kripke, M. L. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9586-9 · Cited by 185
“One approach to accomplish this has been termed “the normalization of blood vessels,” defined as the pruning of blood vessels within neoplasms and reduction of increased vessel permeability [65–67].”
BackgroundHuber, P. E., Bischof, M., Jenne, J., Heiland, S., Peschke, P., Saffrich, R., Gröne, H.-J., Debus, J., Lipson, K. E., & Abdollahi, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1668 · Cited by 185
Dome, B., Timar, J., Dobos, J., Meszaros, L., Raso, E., Paku, S., Kenessey, I., Ostoros, G., Magyar, M., Ladanyi, A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4654 · Cited by 184
“(32, 33) regarding the clinical effects of anti-VEGF therapy.”
BackgroundKunz-Schughart, L. A., Schroeder, J. A., Wondrak, M., van Rey, F., Lehle, K., Hofstaedter, F., & Wheatley, D. N. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00248.2005 · Cited by 184
“Mechanistic studies designed to gain a better understanding of, and an ability to manipulate, the angiogenic process in health and disease have intensified during the past 30 years, having been stimulated by Folkman’s (2, 16, 19, 25, 27) initial hypotheses regarding the angiogenic switch during tumor cell growth and t…”
Perivascular nitric oxide gradients normalize tumor vasculature
Kashiwagi, S., Tsukada, K., Xu, L., Miyazaki, J., Kozin, S. V., Tyrrell, J. A., Sessa, W. C., Gerweck, L. E., Jain, R. K., & Fukumura, D. (2008) · Nature Medicine · doi:10.1038/nm1730 · Cited by 183
Self-citationLu-Emerson, C., Duda, D. G., Emblem, K. E., Taylor, J. W., Gerstner, E. R., Loeffler, J. S., Batchelor, T. T., & Jain, R. K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9575 · Cited by 179
“Indeed, several preclinical studies support this notion.(24,26,30,31) More impor-”
Self-citation(2011) · International Review of Cell and Molecular Biology · doi:10.1016/b978-0-12-386041-5.00003-0 · Cited by 182
“Considerable work suggests that the high expression of VEGF within tumors is one reason why pericyte coverage is decreased compared to normal vascular beds (Greenberg et al., 2008; Jain, 2005) and why the vessels within the tumor microenvironment are highly permeable.”
InfluentialThe VEGF family in cancer and antibody-based strategies for their inhibition
Sullivan, L. A., & Brekken, R. A. (2010) · mAbs · doi:10.4161/mabs.2.2.11360 · Cited by 181
Scaling rules for diffusive drug delivery in tumor and normal tissues
Baish, J. W., Stylianopoulos, T., Lanning, R. M., Kamoun, W. S., Fukumura, D., Munn, L. L., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018154108 · Cited by 182
“Antiangiogenic treatment is known to reduce vascular permeability and interstitial fluid pressures within the tumor that may allow unperfused vessels to regain flow (2, 21), thus possibly spanning unperfused voids and reducing δmax.”
BackgroundResultInfluentialSelf-citationFrom Nanotechnology to Nanomedicine: Applications to Cancer Research
Seigneuric, R., Markey, L., S.A. Nuyten, D., Dubernet, C., T.A. Evelo, C., Finot, E., & Garrido, C. (2010) · Current Molecular Medicine · doi:10.2174/156652410792630634 · Cited by 182
“Taking advantage of this EPR effect [108, 111, 112, 116] (see Fig.”
BackgroundThe pro-tumorigenic host response to cancer therapies
Shaked, Y. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0209-6 · Cited by 181
Dormancy of Solitary Metastatic Cells
Townson, J. L., & Chambers, A. F. (2006) · Cell Cycle · doi:10.4161/cc.5.16.2864 · Cited by 181
STUB1/CHIP is required for HIF1A degradation by chaperone-mediated autophagy
Ferreira, J. V., Fôfo, H., Bejarano, E., Bento, C. F., Ramalho, J. S., Girão, H., & Pereira, P. (2013) · Autophagy · doi:10.4161/auto.25190 · Cited by 181
Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape
Chouaib, S., Messai, Y., Couve, S., Escudier, B., Hasmim, M., & Noman, M. Z. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00021 · Cited by 180
“Indeed, tumor vessels are labyrinthine and branched in an irregular and chaotic manner with uneven diameters due to the compression of their walls by tumor or stromal cells (Jain, 1988, 2005; Nagy et al., 2010).”
BackgroundInfluentialRole of the VEGF/VEGFR Axis in Cancer Biology and Therapy
(2012) · Advances in Cancer Research · doi:10.1016/b978-0-12-386503-8.00006-5 · Cited by 180
Conscripts of the infinite armada: systemic cancer therapy using nanomaterials
Scheinberg, D. A., Villa, C. H., Escorcia, F. E., & McDevitt, M. R. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.38 · Cited by 180
Review of cellular mechanotransduction
Wang, N. (2017) · Journal of Physics D: Applied Physics · doi:10.1088/1361-6463/aa6e18 · Cited by 178
Role of vascular normalization in benefit from metronomic chemotherapy
Mpekris, F., Baish, J. W., Stylianopoulos, T., & Jain, R. K. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700340114 · Cited by 178
“Furthermore, in previous work (7) we showed that an increase in TSP-1 led to normalization of the tumor vessels, characterized by decreases in vascular permeability and diameter accompanied by an increase in functional vessel density (12, 15, 44).”
BackgroundInfluentialSelf-citationNanoformulations for combination or cascade anticancer therapy
Miao, L., Guo, S., Lin, C. M., Liu, Q., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.003 · Cited by 178
“In the light of this issue, drugs designed to modulate the stroma such as anti-angiogenic drugs [20, 21], TGF-β inhibitors [22, 23] and hedgehog inhibitors, provide a new strategy to overcome this type of drug resistance and improve the anti-cancer therapy.”
BackgroundMechanisms of resistance to antiangiogenesis therapy
Azam, F., Mehta, S., & Harris, A. L. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.020 · Cited by 178
Immune Priming of the Tumor Microenvironment by Radiation
Jiang, W., Chan, C. K., Weissman, I. L., Kim, B. Y. S., & Hahn, S. M. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.09.007 · Cited by 178
New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications
Wang, Y., Wang, L., Chen, C., & Chu, X. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0766-4 · Cited by 178
Huang, D., Sun, L., Huang, L., & Chen, Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020124 · Cited by 176
“In addition, the proliferating cancer cells in the center of the tumor tissue will form excessive pressure and compress the blood vessels and lymphatic vessels, leading to vascular collapse [88,94,95].”
BackgroundO'Connor, J. P., Jackson, A., Asselin, M.-C., Buckley, D. L., Parker, G. J., & Jayson, G. C. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70196-7 · Cited by 174
Krzywinska, E., Kantari-Mimoun, C., Kerdiles, Y., Sobecki, M., Isagawa, T., Gotthardt, D., Castells, M., Haubold, J., Millien, C., Viel, T., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01599-w · Cited by 176
Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity
Martin, J. D., Fukumura, D., Duda, D. G., Boucher, Y., & Jain, R. K. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027094 · Cited by 175
“Jain RK. 2005.”
Self-citationCT Perfusion in Oncologic Imaging: A Useful Tool?
García-Figueiras, R., Goh, V. J., Padhani, A. R., Baleato-González, S., Garrido, M., León, L., & Gómez-Caamaño, A. (2013) · American Journal of Roentgenology · doi:10.2214/ajr.11.8476 · Cited by 175
“Initially, anti–VEGF receptor agents decrease tumor vessel permeability and interstitial fluid pressure in a process of normalization of the structure and function of tumor vasculature [89] that, transiently, causes an increase in tumor BF and affects permeability-surface area product values, a circumstance that might…”
BackgroundSeynhaeve, A. L. B., Hoving, S., Schipper, D., Vermeulen, C. E., aan de Wiel-Ambagtsheer, G., van Tiel, S. T., Eggermont, A. M. M., & ten Hagen, T. L. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1599 · Cited by 173
“proposed as a major contribution to the observed clinical outcome (9, 10).”
BackgroundPhysical Chemistry of Nanomedicine: Understanding the Complex Behaviors of Nanoparticles in Vivo
Lane, L. A., Qian, X., Smith, A. M., & Nie, S. (2015) · Annual Review of Physical Chemistry · doi:10.1146/annurev-physchem-040513-103718 · Cited by 175
Pathological angiogenesis and inflammation in tissues
Jeong, J.-H., Ojha, U., & Lee, Y. M. (2021) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01287-2 · Cited by 174
“The abnormal vasculature decreases efficiencies for oxygen and drug delivery, which can be a target of antiangiogenic agents acting on normalization of tumor vasculature (Jain 2005; Liu et al.”
BackgroundHainaud, P., Contrerès, J.-O., Villemain, A., Liu, L.-X., Plouët, J., Tobelem, G., & Dupuy, E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4226 · Cited by 175
“The inhibition of VEGF signaling tends to normalize tumor vasculature (4).”
BackgroundReceptor Tyrosine Kinase-Mediated Angiogenesis
Jeltsch, M., Leppanen, V.-M., Saharinen, P., & Alitalo, K. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009183 · Cited by 175
“The current antiangiogenic drugs reduce tumor blood vessels, resulting in the “normalization” of the remaining vasculature, with less vascular leakiness, and improved pericyte coating and blood flow (Jain 2005).”
BackgroundYan, S. B., Peek, V. L., Ajamie, R., Buchanan, S. G., Graff, J. R., Heidler, S. A., Hui, Y.-H., Huss, K. L., Konicek, B. W., Manro, J. R., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9912-9 · Cited by 167
“Tumor vessel normalization describes a process whereby a tortuous, poorly perfused vascular network is converted to one that consists of directionally-aligned, highly perfused, pericyte-covered vessels [36].”
BackgroundDopamine Increases the Efficacy of Anticancer Drugs in Breast and Colon Cancer Preclinical Models
Sarkar, C., Chakroborty, D., Chowdhury, U. R., Dasgupta, P. S., & Basu, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1778 · Cited by 174
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
Quant, E. C., Norden, A. D., Drappatz, J., Muzikansky, A., Doherty, L., LaFrankie, D., Ciampa, A., Kesari, S., & Wen, P. Y. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-006 · Cited by 173
VEGF/VEGFR signalling as a target for inhibiting angiogenesis
Kiselyov, A., Balakin, K. V., & Tkachenko, S. E. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.1.83 · Cited by 172
“It should be noted that the precise mechanism(s) of the synergy observed in clinics are not clearly understood yet, and alternative hypotheses were proposed to explain this phenomenon [240].”
BackgroundVascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
Georganaki, M., van Hooren, L., & Dimberg, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03081 · Cited by 172
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers
Harrington, K. J., Billingham, L. J., Brunner, T. B., Burnet, N. G., Chan, C. S., Hoskin, P., Mackay, R. I., Maughan, T. S., Macdougall, J., McKenna, W. G., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.240 · Cited by 170
“For example, in studies involving drugs that modulate angiogenesis, it is reasonable to hypothesise that vascular normalisation before starting RT may be associated with a better treatment outcome (Jain, 2005).”
BackgroundTumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy
Johansson, A., Hamzah, J., Payne, C. J., & Ganss, R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118296109 · Cited by 172
“Intriguingly, vascular remodeling under low-dose TNFα treatment as shown here is reminiscent of transient vascular normalization under VEGF blockade, which improves drug penetration and enhances chemotherapy (34).”
BackgroundEffect of Tumor Microenvironment Modulation on the Efficacy of Oncolytic Virus Therapy
Kurozumi, K., Hardcastle, J., Thakur, R., Yang, M., Christoforidis, G., Fulci, G., Hochberg, F. H., Weissleder, R., Carson, W., Chiocca, E. A., et al. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm229 · Cited by 172
Ellis, M. J., Tao, Y., Young, O., White, S., Proia, A. D., Murray, J., Renshaw, L., Faratian, D., Thomas, J., Dowsett, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3034 · Cited by 173
Rapisarda, A., Hollingshead, M., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Gehrs, B., Raffeld, M., Kinders, R. J., Parchment, R., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0274 · Cited by 171
“On the other hand, inhibition of VEGF signaling may be associated with a transient “normalization window,” which would improve tumor oxygenation and delivery of chemotherapy (19).”
BackgroundTargeted Radiotherapy with Gold Nanoparticles: Current Status and Future Perspectives
Ngwa, W., Kumar, R., Sridhar, S., Korideck, H., Zygmanski, P., Cormack, R. A., Berbeco, R., & Makrigiorgos, G. M. (2014) · Nanomedicine · doi:10.2217/nnm.14.55 · Cited by 171
Tumor hypoxia and radiotherapy: A major driver of resistance even for novel radiotherapy modalities
Beckers, C., Pruschy, M., & Vetrugno, I. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.11.006 · Cited by 167
Macrophage regulation of tumor angiogenesis: Implications for cancer therapy
Squadrito, M. L., & De Palma, M. (2011) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.04.005 · Cited by 170
VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer
Waldner, M. J., Wirtz, S., Jefremow, A., Warntjen, M., Neufert, C., Atreya, R., Becker, C., Weigmann, B., Vieth, M., Rose-John, S., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100438 · Cited by 170
“2864 VEGFR links inflammation and tumorigenesis | Waldner et al. cells, which is derived from the detection of VEGF receptors on several lines of tumors (Jain et al., 2006; Ellis and Hicklin, 2008).”
Scholz, A., Harter, P. N., Cremer, S., Yalcin, B. H., Gurnik, S., Yamaji, M., Di Tacchio, M., Sommer, K., Baumgarten, P., Bähr, O., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505505 · Cited by 169
“In addition, and coinciding with the elimination of macrophages, blocking of Ang-2 led to “vessel normalization,” as evidenced by pruning of the chaotic vasculature, decreased vascular permeability and increased pericyte coverage (Jain, 2005).”
Helfrich, I., Scheffrahn, I., Bartling, S., Weis, J., von Felbert, V., Middleton, M., Kato, M., Ergün, S., Augustin, H. G., & Schadendorf, D. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091846 · Cited by 170
“This results in vessel stabilization and reduced vascular permeability, which facilitates access of coadministered chemotherapeutic drugs (Jain 2005).”
A Systematic Review of Biosynthesized Metallic Nanoparticles as a Promising Anti-Cancer-Strategy
Andleeb, A., Andleeb, A., Asghar, S., Zaman, G., Tariq, M., Mehmood, A., Nadeem, M., Hano, C., Lorenzo, J. M., & Abbasi, B. H. (2021) · Cancers · doi:10.3390/cancers13112818 · Cited by 170
“Owing to effectiveness of this therapy, several studies have been reported to block signaling of VEGF, PDGF, EDGR, angiopoietin- key contributors of neovascularization [61].”
BackgroundThe Extracellular Matrix of Blood Vessels
Eble, J., & Niland, S. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787846757 · Cited by 170
Rini, B. I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1989 · Cited by 169
Metadata
- Authors
- Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Science
- Published
- 2005-01-07
- Volume
- 307
- Issue
- 5706
- Pages
- 58-62
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2006202974
- Cited by
- 5,527
- References
- 56
- Citations by year
- 2026: 245 · 2025: 212 · 2024: 202 · 2023: 220 · 2022: 236 · 2021: 279 · 2020: 245 · 2019: 236 · 2018: 219 · 2017: 236 · 2016: 252 · 2015: 292 · 2014: 307 · 2013: 361 · 2012: 350
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- tumor vasculature normalization, anti-angiogenic therapy, tumor hypoxia, tumor oxygenation, drug delivery to tumors, combination cancer therapy, regenerative medicine, vascular function
- MeSH terms
- Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Cell Hypoxia, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.